Xgeva 120 MG/1.7 ML vial 1.7ML
Ended Awarded Last action
- Contract number
- SPE2DR26F0ZN9
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $27,821
Award facts
- Contract value 100% obligated
- $27,820.73 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, awarded on January 8, 2026, to AmerisourceBergen Drug Corp (a subsidiary of Cencora, Inc.) by the Defense Logistics Agency, provides $27.8K for the supply of XGEVA 120 mg/1.7 mL vials. The contract is a firm fixed-price, non-set-aside award with a completion date of January 9, 2026, and will be performed at the awardee's facility in Conshohocken, Pennsylvania. XGEVA (denosumab) is a bone-protective monoclonal antibody used primarily in oncology and orthopedic applications to prevent skeletal-related events in patients with bone metastases or multiple myeloma, making it a critical pharmaceutical supply for military medical treatment facilities and veteran healthcare systems.
This delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999 through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen serves as a prime vendor for the Defense Logistics Agency's Medical Supply Chain, delivering a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The parent company, Cencora, Inc., also maintains a separate $999,999,999 IDC with DLA through December 31, 2031, underscoring the company's significant role in federal pharmaceutical procurement and its demonstrated capability to meet critical government medical supply requirements through competitive, full and open contracting.
Quick answers
Who was awarded contract SPE2DR26F0ZN9?
SPE2DR26F0ZN9 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26F0ZN9 worth?
The government has obligated $27,821 on SPE2DR26F0ZN9.
Is contract SPE2DR26F0ZN9 an order under another contract?
Yes. SPE2DR26F0ZN9 is a delivery order under SPE2DR25D1205, an indefinite delivery contract.
Was contract SPE2DR26F0ZN9 competed?
The extent of competition for SPE2DR26F0ZN9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award